Vland Biotech(SH:603739) Ge Long Hui·2025-11-24 10:16Core Viewpoint - The company, Weilan Bio (603739.SH), currently lacks the necessary production processes for synthetic biology products, which involve complex separation and purification techniques, indicating significant challenges in commercialization [1] Group 1 - The production of synthetic biology products requires advanced separation and purification processes, which the company does not currently possess [1] - The purification process is noted to be particularly difficult, suggesting a need for further development before the company can effectively produce these products [1] - Future production may also involve regulatory approvals, product selection, and market promotion, all of which are expected to have long cycles and significant challenges, leading to major uncertainties in commercialization [1] Group 2 - The company anticipates that these challenges will not have a significant impact on its operations in the near term [1]